SCHEMBL4064980

SCHEMBL4064980

CC(=O)OCc1cc(C)nc(C)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
CYP3A4 P08684 1/20 0.45
IDH1 O75874 1/20 0.41
CA2 P00918 1/20 0.40
HSD17B10 Q99714 3/20 0.39
LMNA P02545 1/20 0.39
TOP2A P11388 1/20 0.39
TOP2B Q02880 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 1/20 0.38
POLB P06746 2/20 0.38
MEN1 O00255 1/20 0.37
THRB P10828 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5666942 0.83 ALDH1A1 (0.64) ALDH1A1CYP3A4IDH1CA2HSD17B10
SCHEMBL3297072 0.82 HTT (0.48) ALDH1A1LMNAKDM4EMAPTPOLB
SCHEMBL5971176 0.79 ALDH1A1 (0.55) ALDH1A1CYP3A4IDH1HSD17B10LMNA
SCHEMBL9686081 0.79 ALDH1A1 (0.55) ALDH1A1CYP3A4IDH1HSD17B10LMNA
SCHEMBL17932863 0.79 ALDH1A1 (0.40) ALDH1A1CYP3A4CA2HSD17B10LMNA
SCHEMBL501663 0.78 ALDH1A1 (0.50) ALDH1A1CYP3A4IDH1CA2HSD17B10
SCHEMBL26781740 0.78 ALDH1A1 (0.53) ALDH1A1CYP3A4IDH1CA2HSD17B10
SCHEMBL27615940 0.77 TDP1 (0.51) ALDH1A1LMNAMAPTMEN1RAB9A
SCHEMBL12160553 0.77 ALDH1A1 (0.57) ALDH1A1CYP3A4IDH1CA2HSD17B10
SCHEMBL18719618 0.76 ALDH1A1 (0.52) ALDH1A1CYP3A4IDH1CA2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317445-B1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2009-03-11 EP disclosed
US-7396840-B2 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION (US) 2008-07-08 US disclosed
US-7084155-B2 Chemokine receptor binding heterocyclic compounds ANORMED (CA) 2006-08-01 US disclosed
US-20060128750-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2006-06-15 US disclosed
US-6864265-B2 Chemokine receptor binding heterocyclic compounds ANORMED, INC. (CA) 2005-03-08 US disclosed
US-20040220207-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2004-11-04 US disclosed
EP-1317445-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2003-06-11 EP disclosed
US-20030018046-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2003-01-23 US disclosed
WO-2002022600-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220207-A1 Chemokine receptor binding heterocyclic compounds CXCR3, ACKR3, CCR2 ALDH1A1 1755/4885CYP3A4 3162/4885IDH1 1605/4885
US-20060128750-A1 Chemokine receptor binding heterocyclic compounds CXCR4, CCR5, CXCR3 ALDH1A1 2001/4885CYP3A4 2593/4885IDH1 953/4885
US-20030018046-A1 Chemokine receptor binding heterocyclic compounds CXCR3, ACKR3, CCR2 ALDH1A1 1755/4885CYP3A4 3162/4885IDH1 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.